Piper Sandler Maintains Neutral on Vicarious Surgical, Adjusts Price Target To $12 from $30 (1-for-30 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains a Neutral rating on Vicarious Surgical (NYSE:RBOT) and adjusts the price target to $12 from $30 following a 1-for-30 reverse stock split.
August 13, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains a Neutral rating on Vicarious Surgical and adjusts the price target to $12 from $30 following a 1-for-30 reverse stock split.
The Neutral rating suggests no strong buy or sell recommendation, and the adjusted price target reflects the reverse stock split. This indicates a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100